midodrine (Orvaten, ProAmatine) (cont.)

Pharmacy Author:
Medical and Pharmacy Editor:

Midodrine may compete with drugs such as metformin (Glucophage), cimetidine (Tagamet), ranitidine (Zantac), procainamide (Pronestyl), triamterene (Dyrenium), flecainide (Tambocor), and quinidine for elimination by renal tubular secretion (clearance through the kidneys). Caution should be used if midodrine must be used with any of these agents.

PREGNANCY: Midodrine has not been adequately evaluated in pregnant women. Due to the lack of conclusive safety data, midodrine should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Midodrine is classified as FDA pregnancy risk category C (Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks).

NURSING MOTHERS: It is not known if midodrine is excreted in breast milk. Due to the lack of safety data, midodrine should be used cautiously in nursing mothers.

SIDE EFFECTS: The most common side effects of midodrine treatment are tingling, tickling, burning or prickling sensation, supine and sitting hypertension, numbness and itching which mainly affects the scalp area, goose bumps, chills, urinary urge, urinary retention, and urinary frequency.

Medically Reviewed by a Doctor on 11/11/2014

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.

Back to Medications Index